<DOC>
	<DOCNO>NCT01119456</DOCNO>
	<brief_summary>A dose escalation study determine maximum tolerate dose IMC-RON8 patient solid tumor . Patients either dosed week , every week .</brief_summary>
	<brief_title>A Study IMC-RON8 Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>The patient histologicallyconfirmed advanced primary recurrent solid tumor respond standard therapy standard therapy available The patient measurable nonmeasurable disease The patient receive major surgery , prior chemotherapy , prior treatment investigational agent device , prior radiation therapy within 28 day prior first dose study therapy The patient Eastern Cooperative Oncology Group performance status ( ECOG PS ) score 02 The patient adequate hematologic function The patient adequate renal function define serum creatinine â‰¤ 1.5 x institutional ULN The patient life expectancy &gt; 3 month The patient receive chemotherapy therapeutic radiation therapy within 28 day prior first dose study therapy The patient ongoing toxicity &gt; Grade 1 associated prior treatment The patient know sensitivity monoclonal antibody therapeutic agent , agent similar biologic composition IMCRON8 The patient receive treatment monoclonal antibody within 6 week prior first dose study therapy The patient receive treatment agent specifically target Ron ligand receptor within 6 week prior first dose study therapy The patient undergone major surgical procedure , open biopsy , experience significant traumatic injury within 28 day prior first dose study therapy The patient ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia ( well control atrial fibrillation permit ) , psychiatric illness/social situation , active bleeding , serious uncontrolled medical disorder opinion investigator The patient know suspected brain leptomeningeal metastasis ( patient history brain metastasis must receive definitive surgery radiotherapy , clinically stable , may take steroid ; patient receive anticonvulsant eligible ) The patient serious nonhealing active wound , ulcer , bone fracture The patient currently use receive thrombolytic agent within 28 day prior first dose study therapy The patient receive fulldose warfarin ( patient receive lowdose warfarin maintain patency permanent , indwell intravenous catheter eligible international normalize ratio &lt; 1.5 ) The patient receive intravenous heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Tumors</keyword>
	<keyword>Macrophage stimulate 1 receptor , human</keyword>
	<keyword>RON protein</keyword>
	<keyword>RON receptor protein tyrosine kinase</keyword>
</DOC>